CRISPR's Rise Sparks Global Debate Over Ethics, Equity and Regulation

CRISPR's ability to modify DNA quickly and cheaply has ignited a booming biotech industry, attracting billions from startups, pharmaceutical firms and agricultural corporations. Its medical applications aim to correct hereditary disorders at the source, while in farming it promises crops that can better endure drought and pests. However, the technology's power and accessibility have sparked fierce ethical debates, especially over germline editing that could affect future generations.

The 2018 case of gene-edited babies in China triggered worldwide condemnation and stricter oversight in many countries, underscoring the gap between scientific progress and policy. Critics also fear a slide toward designer traits and a new form of eugenics, as well as the risk that costly therapies will deepen global health inequities. The lack of uniform international regulations creates opportunities for jurisdictions with lax rules to become testing grounds, raising concerns about safety and fairness. Scholars argue that broader democratic participation is needed to shape policies that balance innovation with societal values.